Thalassemia as a Hypercoagulable State

Maria D Cappellini, MD, Khaled M Musallam, MD and Ali T Taher, MD

Abstract
Although the life expectancy of thalassemia patients has markedly improved over the last few decades, patients still suffer from many complications of this congenital disease. The presence of a high incidence of thromboembolic events, mainly in thalassemia intermedia, has led to the identification of a hypercoagulable state in these patients. In this article, the molecular and cellular mechanisms leading to hypercoagulability in thalassemia are highlighted, with a special focus on thalassemia intermedia, being the type with the highest incidence of thrombotic events as compared with other types of thalassemia. Clinical experience and available clues regarding optimal management are also discussed.

Keywords
Thalassemia, hypercoagulability, thromboembolism, stroke, splenectomy, transfusion

Pathophysiology
Hypercoagulability in patients with thalassemia has been attributed to several factors (see Figure 1). It is often a combination of these factors that leads to TEE.

It is widely accepted that patients with thalassemia have chronically activated platelets and enhanced platelet aggregation, as confirmed by the increased expression of CD62P (P-selectin) and CD63, markers of in vivo platelet activation. Splenectomised thalassemia patients have high platelet counts, but with a shorter lifespan due to enhanced consumption. It has also been shown that splenectomized TM and non-splenectomized TI patients have four to 10 times higher levels of metabolites of prostacyclin (PGI2) and thromboxane A2, both markers of haemostatic activity, than controls. However, no significant difference was found between TM and TI patients.

Three main factors highlight the pathophysiology of TI: ineffective erythropoiesis, chronic anemia/hemolysis, and iron overload secondary to increased intestinal absorption. The extreme diversity in phenotypic expression within the diagnosis of TI itself led to a wide variation in observed clinical complications and management practices. Among the medical complications of TI that were found to occur at high rates, even more frequently than in patients with TM, are thromboembolic events (TEE). Here, we review current evidence on TEE in thalassemia patients, with special emphasis on TI.

Furthermore, the oxidation of globin subunits in thalassemia erythroid cells leads to the formation of hemichromes which precipitate, instigating hem disintegration and the eventual release of toxic non-transferrin-bound iron species. The free iron in turn catalyzes the formation of reactive oxygen species, leading to oxidation of membrane proteins and formation of red-cell ‘senescence’ antigens such as phosphatidylserine, which cause the thalassaemic red blood cells (RBCs) to become rigid and deformed and to aggregate, resulting in premature cell removal. Thalassemic RBCs with negatively charged
Thalassemia

Figure 1: Factors Contributing to Hypercoagulability in Thalassemia

Inherited thrombophilia does not play a role in the hypercoagulability of thalassemia, but high levels of antiphospholipid antibodies and low protein C and S levels have been documented. The presence of cardiac, hepatic or endocrine dysfunction in patients with severe iron overload may also contribute to hypercoagulability in thalassemia.

Clinical Implications

Epidemiologic data on TEE in thalassemia are scarce. Borgna-Pignatti et al. surveyed nine Italian pediatric thalassemia centers, observing that 4% of the 683 patients with TM and 9.6% of the 52 patients with TI had experienced a TEE. The same group showed six years later that 1.1% of 720 patients with TM in seven Italian centers had thrombosis. Cappellini et al. followed up 83 patients with TI over 10 years, 82 of whom were splenectomized and found that 29% (24/83) experienced a venous TEE. One study directly implicated TEE as the cause of death in 2.5% of transfusion-dependent thalassemia patients. After examining data from 8,860 patients in the Mediterranean area and Iran, Taher et al. observed that TEE occurred 4.38 times (95% confidence interval [CI] 3.14–6.10, p<0.001) more frequently in TI than TM, with more venous events occurring in TI and more arterial events occurring in TM. It was found that 14% of mortalities in the whole group were due to TEE. Age above 20 years, splenectomy, family history of TEE and previous TEE were identified as the main risk factors for thrombosis in TI. Furthermore, the study showed that 68% of TI patients that had a TEE had an average hemoglobin level of <9 g/dl and only 33% were receiving regular blood transfusions, whereas 94% were splenectomized. Moreover, patients receiving aspirin therapy had a significantly lower rate of recurrent TEE.

The evidence for brain involvement in thalassemia dates back to 1972, when 20% of 138 TM patients in Greece were found to have neurologic deficits compatible with transient ischemic attacks (TIAs). Further evidence of TIAs causing neurological symptoms, such as headaches, hemiparesis and seizures, was shown in 2.2% of patients with TM in Italy. Although overt stroke occurs more frequently in TM than TI (28 versus 9%, respectively), it has been shown that as many as 37.5% of patients with TI have asymptomatic brain damage on magnetic resonance imaging (MRI). A more recent study on Lebanese patients determined that splenectomized adults with TI show a rate of silent white matter lesions as high as 60%. The occurrence and multiplicity of the lesions were associated with older age (mean age of 36.1 years for lesion-positive patients versus 26.1 years for lesion-negative patients) and transfusion naiveté (83.3% of lesion-positive patients have never had a transfusion versus 25% of lesion-negative patients). Another study from Iran followed to confirm these findings.

In order to obtain much-needed clinical data concerning the optimal management of patients with TI, the Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemcity (OPTIMAL CARE) study evaluated 584 patients with TI at six comprehensive care centres (Lebanon, Italy, Iran, Egypt, United Arab Emirates and Oman) for the associations between patient and disease characteristics, treatment received and the rate of clinical complications. Thrombosis was the fifth most common complication, affecting 14% of the patient population. On multivariate analysis, splenectomy, age above 35 years and a serum ferritin level ≥1,000 μg/l were associated with a higher risk of thrombosis. Conversely, a positive history of transfusion and a hemoglobin level ≥9 g/dl were found to be protective against thrombosis (see Table 1). A higher occurrence of TEE with advancing age was also observed. In an effort to further understand the effect of splenectomy on the risk of TEE, a substudy of OPTIMAL CARE examined the characteristics of splenectomized patients with TI who developed TEE, aiming to identify high-risk patients who deserve further consideration for preventive strategies. Splenectomized patients with documented TEE (Group I, n=73) were age- and sex-matched to splenectomized patients without TEE (Group II) and non-splenectomized patients without TEE (Group III).
study determined that splenectomized TI patients who experience TEE are characterized by high nucleated RBC (≥300 x 10^6/l) and platelet counts (≥500 x 10^9/l) and are more likely to have evidence of pulmonary hypertension (PHT) and be transfusion-naïve. As such, it was suggested that splenectomized TI patients at risk of developing TEE may be identified early on by these laboratory markers, presence of PHT and transfusion status.36 The study further examined how long it took for a TEE to develop following splenectomy and found the median time to thrombosis to be eight years.35 This delay indicates that TEE in splenectomized patients with TI is not an acute complication, but a manifestation of a chronic underlying process, further emphasizing the need for a long-term treatment modality for prevention.36

Potential Preventive Strategies

Reduction of the proportion of circulating RBCs with thrombogenic potential may be achieved by introducing blood transfusions and may account for the lower rate of TEE in transfused versus non-transfused patients in previous studies.3,4,28 As such, transfusion therapy may be worthwhile to prevent the occurrence of TEE and other complications3 in TI patients for whom current practice does not necessarily recommend transfusions. Rather than adhering to the regular transfusion regimens implemented in TM, blood transfusion, if initiated in patients with TI, should be individually tailored to meet patient needs. Although introduction of blood transfusions will increase the rate of iron accumulation, effective methods of iron chelation are now available and the benefits of transfusion therapy may greatly outweigh the cost and inconvenience of iron chelation therapy.35 This approach requires prospective evaluation. Since splenectomy is a major contributor to TEE in patients with thalassemia,36 reassessment of the procedure and appropriate risk-benefit evaluation prior to any attempt at splenectomy are called for. This is also essential in line with recent evidence on the high rates of other clinical complications after splenectomy,3 along with the well-known increased susceptibility to infection.36

The literature lacks proper evidence on the role of antiplatelet or anticoagulant agents in the management of thalassemia.3 The lower recurrence rate of TEE in TI patients who took aspirin after their first TEE, when compared with those who did not, suggests a potential role for aspirin.3 Moreover, the association of higher platelet counts with TEE in patients with TI further suggests a role for aspirin in this patient population.28 Fetal hemoglobin-inducing agents, such as hydroxycarbamide decitabine and decitabine, were also shown to lower plasma markers of thrombin generation.28 Hydroxycarbamide may modulate hypercoagulability in several ways: it may reduce phospholipid expression on the surface of RBCs and platelets and decrease RBC adhesion to thrombospondin, a thrombin-sensitive protein.28 It may also decrease the count of leukocytes, particularly monocytes expressing transcription factor, in addition to being a nitric oxide donor.36

It is recommended that each patient be assessed individually and assigned a personalized thrombotic risk based on intrinsic and extrinsic factors. High nucleated RBC and platelet counts, evidence of PHT and transfusion naïveté can be used as indicators of TEE for splenectomised patients with TI and could be practical in the clinical setting.35 Such a risk assessment model would be valuable in identifying high-risk patients and targeting them for further testing. Several diagnostic tests are being explored to help identify patients at risk, with promising preliminary results.36

The hypercoagulable state in thalassemia is due to multiple elements, a combination of which is often the drive behind a clinical TEE. Splenectomy and transfusion naïveté are increasingly highlighted as important risk factors for TEE, especially in patients with TI. An individualized approach is recommended to establish an optimal strategy for preventing the occurrence of this complication of thalassemia.

### Table 1: Predictors of Thrombosis in the Overview on Practices in Thalassemia Intermedia Management Aiming for Lowering Complication Rates Across a Region of Endemicity Study

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adjusted OR</th>
<th>95 % CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;35</td>
<td>2.59</td>
<td>1.39–4.87</td>
<td>0.003</td>
</tr>
<tr>
<td>Female</td>
<td>1.27</td>
<td>0.74–2.19</td>
<td>0.387</td>
</tr>
<tr>
<td>Hemoglobin ≥9 g/dl</td>
<td>0.41</td>
<td>0.23–0.71</td>
<td>0.001</td>
</tr>
<tr>
<td>Ferritin ≥1,000 μg/l</td>
<td>1.86</td>
<td>1.09–3.16</td>
<td>0.023</td>
</tr>
<tr>
<td>Splenectomy</td>
<td>6.59</td>
<td>3.09–14.05</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Transfusion</td>
<td>0.28</td>
<td>0.16–0.48</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hydroxycarbamide</td>
<td>0.56</td>
<td>0.28–1.10</td>
<td>0.090</td>
</tr>
<tr>
<td>Iron chelation</td>
<td>0.97</td>
<td>0.56–1.68</td>
<td>0.912</td>
</tr>
</tbody>
</table>

CI = confidence interval, OR = odds ratio.